Namilumab

Phase 2Monoclonal antibody

Takeda

Namilumab is one of 124 small molecule programs targeting Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

Cardiac SarcoidosisActive, not recruiting

Pulmonary SarcoidosisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

ArthritisPhase 2

Active, not recruiting

Cardiac SarcoidosisPhase 2

Active, not recruiting

Pulmonary SarcoidosisPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Namilumab

Takeda

Phase 2

3 4

Simponi

Johnson & Johnson

Preclinical

19 5

Remicade

OOrganon and Co

Preclinical

43 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Completed· Takeda logo

Takeda·Phase 2·NCT02379091·108 enrolled

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

Terminated· Takeda logo

Takeda·Phase 2·NCT02393378·7 enrolled

A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis

Completed· Takeda logo

Takeda·Phase 1·NCT01317797·24 enrolled

Psoriasis1 trial

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

Completed· Takeda logo

Takeda·Phase 2·NCT02129777·122 enrolled

Pulmonary Sarcoidosis1 trial

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Terminated·KKinevant Sciences GmbH·Phase 2·NCT05314517·107 enrolled

Cardiac Sarcoidosis1 trial

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

Terminated·KKinevant Sciences GmbH·Phase 2·NCT05351554·1 enrolled

Arthritis1 trial

Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis

Completed·IIzana Bioscience Ltd.·Phase 2·NCT03622658·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Namilumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Namilumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Namilumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Takeda

Namilumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Psoriasis1 trial

Pulmonary Sarcoidosis1 trial

Cardiac Sarcoidosis1 trial

Arthritis1 trial

References

Drug Info

Quick Facts

Related News